Kranendonk Josephine, Vermulst Ad A, van der Veen Daphne, Kramers Cornelis, Warlé Michiel C, Reijnen Michel M P J
Department of Surgery, Radboud University Medical Center, Route 618, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Geestelijke Gezondheidszorg (Mental Health Care) Oost-Brabant, Boekel, The Netherlands.
Cardiovasc Intervent Radiol. 2025 Feb;48(2):157-166. doi: 10.1007/s00270-024-03946-z. Epub 2025 Jan 16.
To investigate the influence of antithrombotic therapy on occurrence of thrombotic and bleeding complications after endovascular aneurysm repair (EVAR).
In this retrospective single-center cohort study, patients who underwent elective endovascular aneurysm repair for abdominal aortic aneurysm were categorized into three antithrombotic groups: single antiplatelet therapy (SAPT), anticoagulants, or dual antiplatelet therapy (DAPT). Outcome measures were the incidence of major adverse cardiovascular events (MACE), prosthetic limb occlusions, and bleeding complications during follow-up.
Among 616 patients (SAPT: n = 450, anticoagulants: n = 84, and DAPT: n = 82), Kaplan-Meier analysis showed no significant difference (log-rank p = 0.37) in incidence of MACE between patients receiving SAPT (20.9%), anticoagulants (25.0%), and DAPT (14.6%) during a median follow-up of almost 4 years. In multivariable Cox regression analysis, only age (HR = 1.03; 95% CI 1.01-1.06, p = 0.01) and American Society of Anesthesiologists (ASA) classification (HR = 1.46; 95% CI 1.12-1.91; p = 0.01) were significant predictors for MACE. Prosthetic limb occlusion was observed in 38 patients during a median follow-up of 4 years; incidence between patients receiving SAPT (5.8%), anticoagulants (10.7%), and DAPT (3.7%) was not significantly different (log-rank p = 0.08). Age (HR = 0.96; 95% CI 0.92-1.00; p = 0.03) and use of anticoagulants (HR = 3.79, 95% CI 1.46-9.83; p < 0.01) were significant predictors for prosthetic limb occlusion. Bleeding complications occurred in 73 patients during median follow-up of almost 4 years, without significant difference (log rank p = 0.06) in incidence between patients receiving SAPT (10.7%), anticoagulants (19.0%), and DAPT (11.0%). ASA classification (HR = 1.74; 95% CI 1.23-2.46; p < 0.01) was a significant predictor for bleeding complications.
Use of anticoagulants after EVAR appears to be associated with a higher risk of prosthetic limb occlusion compared to the use of single or dual antiplatelet therapy.
探讨抗栓治疗对血管内动脉瘤修复术(EVAR)后血栓形成和出血并发症发生情况的影响。
在这项回顾性单中心队列研究中,接受择期腹主动脉瘤血管内动脉瘤修复术的患者被分为三个抗栓治疗组:单一抗血小板治疗(SAPT)、抗凝治疗或双重抗血小板治疗(DAPT)。观察指标为随访期间主要不良心血管事件(MACE)、人工血管肢体闭塞和出血并发症的发生率。
在616例患者中(SAPT组:n = 450,抗凝治疗组:n = 84,DAPT组:n = 82),Kaplan-Meier分析显示,在近4年的中位随访期内,接受SAPT治疗(20.9%)、抗凝治疗(25.0%)和DAPT治疗(14.6%)的患者MACE发生率无显著差异(对数秩检验p = 0.37)。在多变量Cox回归分析中,只有年龄(HR = 1.03;95%CI 1.01 - 1.06,p = 0.01)和美国麻醉医师协会(ASA)分级(HR = 1.46;95%CI 1.12 - 1.91;p = 0.01)是MACE的显著预测因素。在4年的中位随访期内,38例患者出现人工血管肢体闭塞;接受SAPT治疗(5.8%)、抗凝治疗(10.7%)和DAPT治疗(3.7%)的患者之间的发生率无显著差异(对数秩检验p = 0.08)。年龄(HR = 0.96;95%CI 0.92 - 1.00;p = 0.03)和抗凝治疗的使用(HR = 3.79,95%CI 1.46 - 9.83;p < 0.01)是人工血管肢体闭塞的显著预测因素。在近4年的中位随访期内,73例患者发生出血并发症,接受SAPT治疗(10.7%)、抗凝治疗(19.0%)和DAPT治疗(11.0%)的患者之间的发生率无显著差异(对数秩检验p = 0.06)。ASA分级(HR = 1.74;95%CI 1.23 - 2.46;p < 0.01)是出血并发症的显著预测因素。
与单一或双重抗血小板治疗相比,血管内动脉瘤修复术后使用抗凝治疗似乎与人工血管肢体闭塞风险较高相关。